These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 1849415

  • 1. Relative role of bone and kidney in the hypercalcaemia associated with the rat Walker carcinosarcoma 256.
    Hurtado J, Esbrit P, Rapado A.
    Eur J Cancer; 1991; 27(1):76-9. PubMed ID: 1849415
    [Abstract] [Full Text] [Related]

  • 2. Osseous and intestinal compartments in the humoral hypercalcemia of malignancy associated to Walker 256 tumor in rats.
    Torres R, de la Piedra C, Rapado A.
    Oncology; 1993; 50(2):148-52. PubMed ID: 8451038
    [Abstract] [Full Text] [Related]

  • 3. The hypercalcaemic syndrome in rats bearing the Walker carcinosarcoma 256.
    Minne H, Raue F, Bellwinkel S, Ziegler R.
    Acta Endocrinol (Copenh); 1975 Mar; 78(3):613-24. PubMed ID: 1173020
    [Abstract] [Full Text] [Related]

  • 4. Effect of a single injection of two new bisphosphonates on the hypercalcemia and hypercalciuria induced by Walker carcinosarcoma 256/B in thyroparathyroidectomized rats.
    Kozak S, Rizzoli R, Trechsel U, Fleisch H.
    Cancer Res; 1987 Dec 01; 47(23):6193-7. PubMed ID: 3677071
    [Abstract] [Full Text] [Related]

  • 5. Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors.
    Onuma E, Azuma Y, Saito H, Tsunenari T, Watanabe T, Hirabayashi M, Sato K, Yamada-Okabe H, Ogata E.
    Clin Cancer Res; 2005 Jun 01; 11(11):4198-203. PubMed ID: 15930357
    [Abstract] [Full Text] [Related]

  • 6. Bone resorption and renal calcium reabsorption in renal cell carcinoma-bearing mice: the effects of bisphosphonate.
    Weissglas M, Löwik C, Schamhart D, Theuns H, Kurth KH, Papapoulos S.
    BJU Int; 2007 Jun 01; 99(6):1530-3. PubMed ID: 17428243
    [Abstract] [Full Text] [Related]

  • 7. Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type.
    Body JJ, Dumon JC.
    Ann Oncol; 1994 Apr 01; 5(4):359-63. PubMed ID: 8075034
    [Abstract] [Full Text] [Related]

  • 8. Prostaglandin E production and hypercalcaemia in rats bearing the Walker carcinosarcoma.
    Seyberth HW, Bonsch G, Müller H, Minne HW, Erlenmaier T, Strein K, Imbeck H, Mrongovius R.
    Br J Cancer; 1980 Sep 01; 42(3):455-61. PubMed ID: 7426347
    [Abstract] [Full Text] [Related]

  • 9. Pamidronate corrects the down-regulation of the renal parathyroid hormone (PTH)/PTH-related peptide (PTHrP) receptor mRNA in rats bearing Walker tumors.
    Yaghoobian J, Morieux C, Denne MA, Bouizar Z, Ureña P, de Vernejoul MC.
    Horm Metab Res; 1998 May 01; 30(5):249-55. PubMed ID: 9660083
    [Abstract] [Full Text] [Related]

  • 10. Renal phosphate threshold and response to pamidronate in humoral hypercalcaemia of malignancy.
    Gurney H, Kefford R, Stuart-Harris R.
    Lancet; 1989 Jul 29; 2(8657):241-4. PubMed ID: 2569054
    [Abstract] [Full Text] [Related]

  • 11. In vivo and in vitro effects of WR-2721 in experimental hypercalcemia in the rat.
    Weiss J, Walker ST, Fallon M, Goldfarb S.
    J Pharmacol Exp Ther; 1986 Sep 29; 238(3):969-73. PubMed ID: 3018229
    [Abstract] [Full Text] [Related]

  • 12. Treatment of cancer associated hypercalcaemia with combined aminohydroxypropylidene diphosphonate and calcitonin.
    Ralston SH, Alzaid AA, Gardner MD, Boyle IT.
    Br Med J (Clin Res Ed); 1986 Jun 14; 292(6535):1549-50. PubMed ID: 3087513
    [Abstract] [Full Text] [Related]

  • 13. Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein.
    Walls J, Ratcliffe WA, Howell A, Bundred NJ.
    Br J Cancer; 1994 Jul 14; 70(1):169-72. PubMed ID: 8018531
    [Abstract] [Full Text] [Related]

  • 14. Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia.
    Gurney H, Grill V, Martin TJ.
    Lancet; 1993 Jun 26; 341(8861):1611-3. PubMed ID: 8099988
    [Abstract] [Full Text] [Related]

  • 15. Vitamin D intoxication causes hypercalcaemia by increased bone resorption which responds to pamidronate.
    Selby PL, Davies M, Marks JS, Mawer EB.
    Clin Endocrinol (Oxf); 1995 Nov 26; 43(5):531-6. PubMed ID: 8548936
    [Abstract] [Full Text] [Related]

  • 16. Normalization of hypercalcemia associated with a decrease in renal calcium reabsorption in Leydig cell tumor-bearing rats treated with WR-2721.
    Hirschel-Scholz S, Caverzasio J, Rizzoli R, Bonjour JP.
    J Clin Invest; 1986 Jul 26; 78(1):319-22. PubMed ID: 3013941
    [Abstract] [Full Text] [Related]

  • 17. [Hypercalcemic activity of Walker carcinosarcoma 256 in the rat].
    Minne H, Ziegler R, Schmitt W, Hilgard P.
    Schweiz Med Wochenschr; 1971 Apr 03; 101(13):481-3. PubMed ID: 5558917
    [No Abstract] [Full Text] [Related]

  • 18. Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia.
    Ralston SH, Gardner MD, Dryburgh FJ, Jenkins AS, Cowan RA, Boyle IT.
    Lancet; 1985 Oct 26; 2(8461):907-10. PubMed ID: 2865417
    [Abstract] [Full Text] [Related]

  • 19. Characterization of calcium transport in the luminal and the basolateral membrane from kidney cortex of hypercalcemic rats bearing the Walker 256 carcinosarcoma.
    de Miguel F, Esbrit P.
    Bone Miner; 1993 Oct 26; 23(1):65-76. PubMed ID: 8274881
    [Abstract] [Full Text] [Related]

  • 20. Treatment of hypercalcaemia with pamidronate in patients with end stage renal failure.
    Davenport A, Goel S, Mackenzie JC.
    Scand J Urol Nephrol; 1993 Oct 26; 27(4):447-51. PubMed ID: 8159916
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.